Host response diagnostic company, MeMed, announced today the FDA has granted the company a breakthrough device designation (BDD) for its MeMed Severity test. According to the company, the test looks to aid clinicians in rapid risk stratification and predicting disease progression, in conjunction with clinical assessments and other laboratory findings.1
The test is based on a host-response technology that measures multiple proteins from a blood sample and applies machine learning to stratify the risk that a patient with an acute infection is likely to deteriorate to severe outcomes within 72 hours, or risk of mortality within 14 days. MeMed believes this can be utilized in hospital emergency departments, as it can help in decision-making related to triage, and treatment. The diagnostic use easy-to-interpret results in under 15 minutes, compatibility with high-throughput analyzers and minimal blood volume requirements.1
“The FDA’s BDD for MeMed Severity validates our commitment to addressing critical healthcare challenges with novel host-response technologies,” MeMed CEO Eran Eden, PhD, said in a statement. “This milestone highlights FDA’s confidence in MeMed’s rigorous development process and the test’s ability to fill a critical gap in sepsis management, equipping clinicians with valuable insights to improve care and save lives."1
Sepsis can be difficult to diagnose, especially as there is not a singular test for the medical emergency. It can be difficult to determine if the body will be set off by an infection and cause the body’s immune system to overreact, which can lead to a whole host of cascading issues including organ dysfunction, septic shock, multi-organ failure, and possibly death.